Pazopanib: an antiangiogenic drug in perspective

被引：16

作者：

Castaneda, Carlos A. ^{[1
]}

Gomez, Henry L. ^{[1
]}

机构：

[1] Inst Nacl Enfermedades Neoplas, Div Med, Lima, Peru

来源：

FUTURE ONCOLOGY | 2009年 / 5卷 / 09期

关键词：

angiogenesis; breast; cervix; glyomas; lung; multiple myeloma; ovarian; pazopanib; renal; sarcomas; thyroid; tyrosine kinase; VEGF; ENDOTHELIAL-GROWTH-FACTOR; RENAL-CELL CARCINOMA; MULTIKINASE ANGIOGENESIS INHIBITOR; METASTATIC COLORECTAL-CANCER; BEVACIZUMAB PLUS IRINOTECAN; FACTOR VEGF OVEREXPRESSION; TYROSINE KINASE INHIBITOR; SOFT-TISSUE SARCOMA; PHASE-II; MULTIPLE-MYELOMA;

D O I：

10.2217/FON.09.112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway, It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

引用

页码：1335 / 1348

页数：14

共 84 条

[61] Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis [J].

Schoenleber, S. J. ;

Kurtz, D. M. ;

Talwalker, J. A. ;

Roberts, L. R. ;

Gores, G. J. .

BRITISH JOURNAL OF CANCER, 2009, 100 (09) :1385-1392

[62] Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis [J].

Shibuya, Masabumi .

BMB REPORTS, 2008, 41 (04) :278-286

[63]

Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469

[64] Randomized study of pazopanib plus lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [J].

Slamon, D. ;

Gomez, H. L. ;

Kabbinavar, F. F. ;

Amit, O. ;

Richie, M. ;

Pandite, L. ;

Goodman, V. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[65]

SLAMON DGH, 2008, ANN ONCOL, V19, pP139

[66]

Sleijfer S, 2007, J CLIN ONCOL, V25

[67]

SLEIJFER S, 2008, ANN ONCOL, V19, P8680

[68] Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) [J].

Sleijfer, Stefan ;

Ray-Coquard, Isabelle ;

Papai, Zsuzsa ;

Le Cesne, Axel ;

Scurr, Michelle ;

Schoeffski, Patrick ;

Collin, Francoise ;

Pandite, Lini ;

Marreaud, Sandrine ;

De Brauwer, Annick ;

van Glabbeke, Martine ;

Verweij, Jaap ;

Blay, Jean-Yves .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3126-3132

[69]

Sloan B, 2008, CURR OPIN INVEST DR, V9, P1324

[70] Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma [J].

Sonpavde, Guru ;

Hutson, Thomas E. ;

Sternberg, Cora N. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (02) :253-261

← 1 2 3 4 5 6 7 8 9 →